SOFINNOVA-PARTNERS
14.10.2020 08:02:10 CEST | Business Wire | Press release
Sofinnova Partners , a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the appointment of Dr. Joe Anderson as Partner in the Sofinnova Crossover Fund, effective immediately.
Dr. Anderson has over 25 years’ experience in the healthcare and life sciences industries. Previously, he was a Partner at Abingworth LLP for over a decade, where he led venture-style investments in public companies and the formation of the firm’s public equities fund. Most recently, Dr. Anderson was Co-Founder and Chief Executive Officer at Arix Bioscience plc, a venture capital firm listed on the London Stock Exchange.
Dr. Anderson has substantial experience as an active Board Member developing innovative life sciences companies in the UK and the US and his investments have involved numerous private and public financing rounds, IPOs, M&As and exits.
Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, commented: “Joe’s arrival signals a decisive moment of growth for the Sofinnova Crossover Fund. It comes on the heels of a number of recent milestones, including two IPOs on the Nasdaq, new investments, positive clinical data and key appointments in our portfolio companies. His extensive experience leading venture capital investments in private and public companies will allow us to continue building on the great work of the Crossover team and positions Sofinnova Partners for further expansion.”
Joe Anderson commented: “I am delighted to join Sofinnova Partners at this exciting time for life sciences in Europe. The firm has been a pioneer in life sciences investing, most recently through the founding of the Sofinnova Crossover Fund -- one of the first of its kind in Europe. Record numbers of companies are being formed from a flourishing science base in Europe. Access to later-stage scale-up capital is crucial as they seek to build and retain value and the need for this kind of investment has never been greater. I look forward to working with my colleagues to further develop this leading European strategy.”
Jacques Theurillat, Partner in the Sofinnova Crossover Fund, commented: “We warmly welcome Joe to the Sofinnova Crossover team. Joe’s knowledge and expertise will further reinforce our experienced team of investment partners, Kinam Hong, Cédric Moreau, Tom Burt and myself, as we support ground-breaking innovations and enable later-stage life sciences companies to reach their full potential.”
Dr. Anderson began his career at the Ciba (now Novartis) Foundation, before joining The Wellcome Trust in 1990 where he became Head of the strategy group. He then moved to the City as a pharmaceuticals analyst at Dresdner Kleinwort Benson, before being appointed Head of Global Healthcare and Portfolio Manager at First State Investments, Commonwealth Bank of Australia, in London. He then joined Abingworth LLP as a Partner for 12 years before moving on to co-found Arix Biosciences in 2016 and lead its IPO on the London Stock Exchange the following year. He holds a Ph.D. in Biochemistry.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, London and Milan, the firm brings together a team of over 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed 500 companies over 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. For more information, please visit: www.sofinnovapartners.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005998/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release
The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e
Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 18:40:00 CET | Press release
Frontgrade processors and radiation-hardened microelectronics support critical spacecraft and instrument functions on NASA’s flagship astrophysics mission Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redunda
Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 16:05:00 CET | Press release
On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con
ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 15:00:00 CET | Press release
ViTAA Medical to Become Key SVS AI Partner, Advancing AI Education and Responsible Adoption in Vascular Care ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer
Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health20.11.2026 14:39:00 CET | Press release
Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approaches to address unmet medical needs in eye health. A combination of complementary scientific expertise Epitech Group has been studying ALIAmides and their role in physiological regulatory mechanisms for over 30 years, building on the research of Rita Levi-Montalcini, the 1986 Nobel Prize in Medicine laureate who first identified the ALIA mechanism. Horus Pharma, for its part, contributes over 20 years of ophthalmology expertise, strong R&D capabilities, and its international presence. Against the backdrop of an aging population
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
